Literature DB >> 20660711

Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation.

Angela M Tatum1, Alan M Watson, Todd D Schell.   

Abstract

The magnitude and complexity of Ag-specific CD8(+) T cell responses is determined by intrinsic properties of the immune system and extrinsic factors, such as vaccination. We evaluated mechanisms that regulate the CD8(+) T cell response to two distinct determinants derived from the same protein Ag, SV40 T Ag (T Ag), following immunization of C57BL/6 mice with T Ag-transformed cells. The results show that direct presentation of T cell determinants by T Ag-transformed cells regulates the magnitude of the CD8(+) T cell response in vivo but not the immunodominance hierarchy. The immunodominance hierarchy was reversed in a dose-dependent manner by addition of excess naive T cells targeting the subdominant determinant. However, T cell competition played only a minor role in limiting T cell accumulation under physiological conditions. We found that the magnitude of the T cell response was regulated by the ability of T Ag-transformed cells to directly present the T Ag determinants. The hierarchy of the CD8(+) T cell response was maintained when Ag presentation in vivo was restricted to cross-presentation, but the presence of T Ag-transformed cells capable of direct presentation dramatically enhanced T cell accumulation at the peak of the response. This enhancement was due to a prolonged period of T cell proliferation, resulting in a delay in T cell contraction. Our findings reveal that direct presentation by nonprofessional APCs can dramatically enhance accumulation of CD8(+) T cells during the primary response, revealing a potential strategy to enhance vaccination approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660711      PMCID: PMC2924944          DOI: 10.4049/jimmunol.0903920

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens.

Authors:  P Grufman; E Z Wolpert; J K Sandberg; K Kärre
Journal:  Eur J Immunol       Date:  1999-07       Impact factor: 5.532

2.  CTLA-4-Mediated inhibition of early events of T cell proliferation.

Authors:  M C Brunner; C A Chambers; F K Chan; J Hanke; A Winoto; J P Allison
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

3.  A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies.

Authors:  Nicole L La Gruta; Katherine Kedzierska; Ken Pang; Richard Webby; Miles Davenport; Weisan Chen; Stephen J Turner; Peter C Doherty
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-17       Impact factor: 11.205

4.  Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.

Authors:  Pavel Otahal; Sandra C Hutchinson; Lawrence M Mylin; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2005-07-15       Impact factor: 5.422

5.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.

Authors:  Li-Xin Wang; Suyu Shu; Gregory E Plautz
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

7.  Insufficient APC capacities of dendritic cells in gene gun-mediated DNA vaccination.

Authors:  Henning Lauterbach; Anton Gruber; Christine Ried; Cedric Cheminay; Thomas Brocker
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

8.  In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice.

Authors:  Kevin Staveley-O'Carroll; Todd D Schell; Marcela Jimenez; Lawrence M Mylin; M Judith Tevethia; Stephen P Schoenberger; Satvir S Tevethia
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

9.  The onset of CD8+-T-cell contraction is influenced by the peak of Listeria monocytogenes infection and antigen display.

Authors:  Brandon B Porter; John T Harty
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  CD8alpha+ dendritic cells selectively present MHC class I-restricted noncytolytic viral and intracellular bacterial antigens in vivo.

Authors:  Gabrielle T Belz; Ken Shortman; Michael J Bevan; William R Heath
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

View more
  4 in total

1.  Dynamics of Tissue-Specific CD8+ T Cell Responses during West Nile Virus Infection.

Authors:  Renan Aguilar-Valenzuela; Jason Netland; Young-Jin Seo; Michael J Bevan; Arash Grakoui; Mehul S Suthar
Journal:  J Virol       Date:  2018-04-27       Impact factor: 5.103

2.  Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach.

Authors:  Colin Campbell; Ranran Zhang; Jeremy S Haley; Xin Liu; Thomas Loughran; Todd D Schell; Réka Albert; Juilee Thakar
Journal:  Front Physiol       Date:  2011-07-11       Impact factor: 4.566

3.  Kinetics of antigen expression and epitope presentation during virus infection.

Authors:  Nathan P Croft; Stewart A Smith; Yik Chun Wong; Chor Teck Tan; Nadine L Dudek; Inge E A Flesch; Leon C W Lin; David C Tscharke; Anthony W Purcell
Journal:  PLoS Pathog       Date:  2013-01-31       Impact factor: 6.823

4.  The 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T Cells.

Authors:  Alan M Watson; L K Metthew Lam; William B Klimstra; Kate D Ryman
Journal:  PLoS Pathog       Date:  2016-07-27       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.